66
Mostly True
United States
The website discusses an experimental pancreatic cancer drug, daraxonrasib, which reportedly doubles survival time compared to chemotherapy, with half of patients living 13 months or longer. The drug targets malfunctioning RAS proteins and has fewer severe side effects than chemotherapy.
The claims regarding the new pancreatic cancer drug daraxonrasib are well-supported by multiple sources. Evidence confirms that daraxonrasib significantly extends survival in patients with advanced pancreatic cancer compared to traditional chemotherapy, with a median survival of 13.2 months versus 6.7 months for chemotherapy. Additionally, the mechanism of action involving cyclophilin A and RAS proteins is corroborated by scientific sources. Overall, the claims are factual and supported by credible evidence.
Individual Claims
80
True
Health & Medicine
A new pancreatic cancer pill called daraxonrasib nearly doubled the survival time of people with advanced pancreatic cancer compared to traditional chemotherapy.
Multiple sources confirm that daraxonrasib significantly extends survival in metastatic pancreatic cancer, with a median overall survival of 13.2 months compared to 6.7 months with chemotherapy. This supports the claim that it nearly doubles survival time. Sources include news-medical.net and Revolution Medicines' press release.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
90
Web Consensus Weight
50
Source Quality Score
85
Source Quality Weight
25
Llm Reasoning Score
80
Llm Reasoning Weight
25
Weighted Total
80
Evidence Summary
3 web sources confirm daraxonrasib nearly doubles survival time compared to chemotherapy.
80
True
Health & Medicine
Half of patients on the new drug lived 13 months or longer after treatment.
Evidence from multiple sources, including oncologynewscentral.com and Revolution Medicines' press release, confirms that the median overall survival for patients on daraxonrasib is 13.2 months, supporting the claim that half of the patients lived 13 months or longer.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
90
Web Consensus Weight
50
Source Quality Score
85
Source Quality Weight
25
Llm Reasoning Score
80
Llm Reasoning Weight
25
Weighted Total
80
Evidence Summary
3 web sources confirm median survival of 13.2 months for daraxonrasib.
80
True
Health & Medicine
The median survival was less than seven months for those on chemotherapy.
The evidence from multiple sources, including news-medical.net, confirms that the median survival for chemotherapy patients is 6.7 months, supporting the claim that it is less than seven months.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
90
Web Consensus Weight
50
Source Quality Score
85
Source Quality Weight
25
Llm Reasoning Score
80
Llm Reasoning Weight
25
Weighted Total
80
Evidence Summary
1 web source confirms median survival of 6.7 months for chemotherapy.
9
False
Health & Medicine
Pancreatic cancer is commonly fueled by malfunctioning RAS proteins.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
None
Web Consensus Weight
0
Source Quality Score
None
Source Quality Weight
0
Llm Reasoning Score
-1
Llm Reasoning Weight
100
Weighted Total
9
Evidence Summary
None
80
True
Health & Medicine
Daraxonrasib acts like a molecular glue by sticking to cyclophilin A and then glomming onto RAS.
Multiple sources, including Wikipedia and PubMed, confirm that daraxonrasib uses a molecular glue mechanism to inhibit RAS proteins by first binding to cyclophilin A. This supports the claim about its mechanism of action.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
90
Web Consensus Weight
50
Source Quality Score
85
Source Quality Weight
25
Llm Reasoning Score
80
Llm Reasoning Weight
25
Weighted Total
80
Evidence Summary
2 web sources confirm daraxonrasib's mechanism as a molecular glue.
